Safety & Efficacy of Intramyocardial Injection of Mesenchymal Precursor Cells on Myocardial Function in LVAD Recipients

PHASE2CompletedINTERVENTIONAL
Enrollment

159

Participants

Timeline

Start Date

July 31, 2015

Primary Completion Date

August 10, 2018

Study Completion Date

August 23, 2019

Conditions
Heart FailureCardiomyopathyVentricular Dysfunction
Interventions
BIOLOGICAL

MPC Intramyocardial Injection

Intramyocardial injection of 150 million mesenchymal precursor cells at the time of LVAD implantation

DRUG

Control Solution

Trial Locations (19)

10032

Columbia University Medical Center, New York

10467

Montefiore Einstein Heart Center, The Bronx

15213

University of Pittsburgh, Pittsburgh

19104

University of Pennsylvania, Philadelphia

21201

University of Maryland, Baltimore

22908

University of Virginia Health Systems, Charlottesville

27710

Duke University, Durham

43210

Ohio State University, Columbus

44195

Cleveland Clinic Foundation, Cleveland

48109

University of Michigan, Ann Arbor

48202

Henry Ford Hospital, Detroit

53726

University of Wisconsin School of Medicine and Public Health, Madison

75093

Baylor Research Institute, Plano

84132

University of Utah, Salt Lake City

90033

University of Southern California, Los Angeles

94305

Stanford University School of Medicine, Stanford

T6G 2B7

University of Alberta Hospital, Edmonton

M5G 2C4

Toronto General Hospital, Toronto

G1V 4G5

Institut Universitaire de Cardiologie de Quebec (Hopital Laval), Québec

All Listed Sponsors
collaborator

National Heart, Lung, and Blood Institute (NHLBI)

NIH

lead

Annetine Gelijns

OTHER

NCT02362646 - Safety & Efficacy of Intramyocardial Injection of Mesenchymal Precursor Cells on Myocardial Function in LVAD Recipients | Biotech Hunter | Biotech Hunter